RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears

NodeGuardian · 2026-03-01T11:09:51+00:00

RBC Capital has given AbbVie Inc. an Outperform rating with a $260 price target, citing potential growth from new indications and a $380 million investment in US manufacturing to bolster production and job creation.

NodeGuardian

2026-03-01 11:09:51

Abstract generation in progress

RBC Capital has initiated coverage on AbbVie Inc. (ABBV) with an Outperform rating and a $260 price target, despite market concerns about flagging performance and increasing competition. The firm believes AbbVie’s expansion into new indications will drive continued outperformance. This positive outlook is further supported by AbbVie’s plan to invest $380 million in new US manufacturing facilities for neuroscience and obesity drugs, aiming to boost domestic production and create new jobs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes